NO20074906L - Polynukleotid som koder for et kimaert molekyl, vertcelle som uttrykker et kimaert molekyl og rekombinant vektor omfattende polynukleotidet - Google Patents

Polynukleotid som koder for et kimaert molekyl, vertcelle som uttrykker et kimaert molekyl og rekombinant vektor omfattende polynukleotidet

Info

Publication number
NO20074906L
NO20074906L NO20074906A NO20074906A NO20074906L NO 20074906 L NO20074906 L NO 20074906L NO 20074906 A NO20074906 A NO 20074906A NO 20074906 A NO20074906 A NO 20074906A NO 20074906 L NO20074906 L NO 20074906L
Authority
NO
Norway
Prior art keywords
chimeric molecule
polynucleotide
host cell
recombinant vector
cell expressing
Prior art date
Application number
NO20074906A
Other languages
English (en)
Other versions
NO331434B1 (no
Inventor
Thomas J Kipps
Sanjai Sharma
Mark Cantwell
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20074906L publication Critical patent/NO20074906L/no
Application filed by Univ California filed Critical Univ California
Publication of NO331434B1 publication Critical patent/NO331434B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Oppfinnelsen vedrører et polynukleotid som koder for et kimært molekyl hvor polynukleotidet omfatter, i rekkefiølge, nukleotidsekvenser som koder fior et proksimalt ekstiacellulært domene (domene III) av et murint CD40 ligand gen og at distalt ekstracellulært domene (domene IV) av et humant CD40 ligand gen. Likeledes vedrører oppfinnelsen også et polynukleotid som koder fior et kimært molekyl hvor polynukleotidet omfiatter, i rekkefiølge, nukleotidsekvenser som koder fior et proksimalt ekstiacellulært domene (domene III) av et humant CD40 ligand gen og et distalt ekstracellulært domene (domene IV) av et humant TNFa ligand gen. En human vertcelle og en rekombinant ekspresjonsvektor er også omtalt.
NO20074906A 1996-12-09 2007-09-27 Kimaert nukleinsyremolekyl, rekombinant ekspresjonsvektor og vertcelle NO331434B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3214596P 1996-12-09 1996-12-09
US08/982,272 US7070771B1 (en) 1996-12-09 1997-12-01 Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
PCT/US1997/022740 WO1998026061A2 (en) 1996-12-09 1997-12-08 Expression vectors containing accessory molecule ligand genes and their use for immunomodulation and treatment of malignancies and autoimmune disease

Publications (2)

Publication Number Publication Date
NO20074906L true NO20074906L (no) 1999-08-09
NO331434B1 NO331434B1 (no) 2011-12-27

Family

ID=26708033

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19992756A NO327411B1 (no) 1996-12-09 1999-06-07 Polynukleotid som koder for en kimaer CD40 ligand.
NO20074906A NO331434B1 (no) 1996-12-09 2007-09-27 Kimaert nukleinsyremolekyl, rekombinant ekspresjonsvektor og vertcelle

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO19992756A NO327411B1 (no) 1996-12-09 1999-06-07 Polynukleotid som koder for en kimaer CD40 ligand.

Country Status (16)

Country Link
US (3) US7070771B1 (no)
EP (4) EP1806360A3 (no)
JP (1) JP4015201B2 (no)
CN (1) CN1221662C (no)
AT (2) ATE547524T1 (no)
AU (1) AU5795798A (no)
BR (1) BR9714004A (no)
CA (2) CA2274498C (no)
DE (1) DE69739220D1 (no)
DK (1) DK0948614T3 (no)
ES (1) ES2321246T3 (no)
IL (3) IL130247A0 (no)
NO (2) NO327411B1 (no)
NZ (1) NZ336092A (no)
PT (1) PT948614E (no)
WO (1) WO1998026061A2 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
EP1173589A1 (en) * 1999-04-16 2002-01-23 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
GB9917180D0 (en) * 1999-07-23 1999-09-22 Univ Sheffield Cell surface receptor
GB0025307D0 (en) * 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
WO2002036769A2 (en) * 2000-10-31 2002-05-10 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
WO2003070271A2 (en) * 2002-02-25 2003-08-28 Isis Innovation Limted Novel complexes for inducing an immune response
US7495090B2 (en) * 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US20080044393A1 (en) * 2004-07-16 2008-02-21 White Robert L Retinal dystrophin transgene and methods of use thereof
WO2008109825A2 (en) * 2007-03-08 2008-09-12 Mayo Foundation For Medical Education And Research Inducing immune-mediated tumor cell death
US20100050276A1 (en) * 2008-08-22 2010-02-25 Brown University Transgenic non-human animal models of apoptosis-mediated conditions
EP2788021B1 (en) 2011-12-09 2017-01-18 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
CA2888193A1 (en) * 2012-10-17 2014-04-24 Eyal Breitbart Treatment methods using adenovirus
US20170173180A1 (en) * 2014-03-27 2017-06-22 The Regents Of The University Of Michigan Cancer immunotherapy compositions and methods
JP6694875B2 (ja) 2014-05-15 2020-05-20 ナショナル ユニヴァーシティ オブ シンガポール 改変ナチュラルキラー細胞及びその使用
CN105567679B (zh) * 2014-10-10 2019-07-05 深圳市北科生物科技有限公司 可分泌型trail蛋白构建物和表达载体
US20180244750A1 (en) 2015-11-02 2018-08-30 Memgen, Llc Methods for treatment of cancer
US11298420B2 (en) 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
KR102660336B1 (ko) 2017-03-27 2024-04-26 내셔널 유니버시티 오브 싱가포르 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도
WO2018191369A1 (en) 2017-04-12 2018-10-18 Memgen, Llc Methods of cd40 and toll like receptor immune activation
US12258381B2 (en) 2018-02-09 2025-03-25 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
CN112055717B (zh) 2018-04-02 2024-04-26 新加坡国立大学 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子
CN112601758A (zh) 2018-08-29 2021-04-02 新加坡国立大学 特异性刺激经基因修饰免疫细胞的存活和扩增的方法
SG11202109057XA (en) 2019-03-05 2021-09-29 Nkarta Inc Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
CN112725379B (zh) * 2021-01-27 2024-08-13 上海南方模式生物科技股份有限公司 人源化cd40基因改造动物模型的构建方法及应用
US11585330B1 (en) * 2021-09-29 2023-02-21 Halliburton Energy Services, Inc. Flow control for geothermal well

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE107362T1 (de) 1986-06-20 1994-07-15 Dainippon Pharmaceutical Co Polypeptid-mutanten des menschlichen tnf und für diese mutanten codierende dns.
WO1988009343A1 (fr) 1987-05-29 1988-12-01 Sagami Chemical Research Center Proteine fusionnee contenant une lymphotoxine
ATE148992T1 (de) 1989-08-16 1997-03-15 Chiron Corp Zusammensetzungen zur hemmung der bildung von proteinhormon und deren verwendungen
US5519119A (en) 1990-09-21 1996-05-21 Ishihara Sangyo Kaisha Ltd. Muteins of TNF pharmaceutical compositions and a method of making
CA2055168A1 (en) 1990-11-21 1992-05-22 Walter Fiers Tnf-muteins
ES2227513T5 (es) 1991-10-25 2009-04-01 Immunex Corporation Citoquina novedosa.
CA2133326C (en) 1992-03-30 2005-03-01 Craig A. Smith Fusion proteins comprising tumor necrosis factor receptor
SK376492A3 (en) 1992-04-02 1995-06-07 Hoffmann La Roche Tnf - muteins and method of their production
EP0615451B1 (en) 1992-05-26 2005-12-07 Immunex Corporation Novel cytokine that binds cd30
AU5098493A (en) 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
EP0656947A1 (en) 1992-08-21 1995-06-14 Schering Corporation Human interleukin-13
US5540926A (en) 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5573924A (en) 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
US5565321A (en) 1993-01-22 1996-10-15 Immunex Corporation Detection of mutations in a CD40 ligand gene
ES2211876T3 (es) 1993-01-22 2004-07-16 Immunex Corporation Deteccion y tratamiento de mutaciones en un gel del ligando de cd40.
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5861310A (en) * 1993-11-03 1999-01-19 Dana-Farber Cancer Institute Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
JPH08127594A (ja) 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
AU1059095A (en) * 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
CA2179196A1 (en) 1993-12-23 1995-06-29 Richard J. Armitage Method of preventing or treating disease characterized by neoplastic cells expressing cd40
WO1995018819A1 (en) 1994-01-07 1995-07-13 Immunex Corporation Ligand that binds fas antigen
CA2188165C (en) 1994-04-28 2007-08-28 Marilyn Kehry Methods for proliferating and differentiating b cells, and uses thereof
US5606023A (en) 1994-05-24 1997-02-25 Thomas Jefferson University Mutant tumor necrosis factor proteins
US5759536A (en) 1994-05-27 1998-06-02 University Technology Corporation Use of fas ligand to supress T-lymphocyte-mediated immune responses
WO1996003141A1 (en) 1994-07-22 1996-02-08 F. Hoffmann-La Roche Ag Pharmaceutical compositions comprising a chimaeric tnf binding protein
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US5888764A (en) * 1995-01-20 1999-03-30 Uab Research Foundation Human fas gene promoter region
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US6016832A (en) * 1997-04-16 2000-01-25 Woodward Governor Company Valve for controlling gas mass flow
EP1016721B1 (en) 1997-09-17 2010-03-10 Mochida Pharmaceutical Co., Ltd. Fas ligand derivative
US7786282B2 (en) * 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) * 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
GB2392158B (en) * 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof

Also Published As

Publication number Publication date
DE69739220D1 (de) 2009-03-05
NO992756D0 (no) 1999-06-07
JP2001505782A (ja) 2001-05-08
PT948614E (pt) 2009-04-20
US7524944B2 (en) 2009-04-28
EP2145958B1 (en) 2012-02-29
CA2274498A1 (en) 1998-06-18
WO1998026061A3 (en) 1998-11-19
CN1246892A (zh) 2000-03-08
EP0948614B1 (en) 2009-01-14
CN1221662C (zh) 2005-10-05
ES2321246T3 (es) 2009-06-03
CA2274498C (en) 2010-06-29
US7906638B2 (en) 2011-03-15
CA2707726C (en) 2013-10-22
NO992756L (no) 1999-08-09
CA2707726A1 (en) 1998-06-18
EP0948614A2 (en) 1999-10-13
WO1998026061A2 (en) 1998-06-18
IL130247A (en) 2008-03-20
NO327411B1 (no) 2009-06-22
NZ336092A (en) 2001-09-28
EP2287309A1 (en) 2011-02-23
AU5795798A (en) 1998-07-03
US20100267129A1 (en) 2010-10-21
NO331434B1 (no) 2011-12-27
US20060183199A1 (en) 2006-08-17
US7070771B1 (en) 2006-07-04
IL130247A0 (en) 2000-06-01
EP1806360A3 (en) 2007-12-12
ATE547524T1 (de) 2012-03-15
EP1806360A2 (en) 2007-07-11
JP4015201B2 (ja) 2007-11-28
EP2145958A1 (en) 2010-01-20
DK0948614T3 (da) 2009-05-11
IL178306A0 (en) 2007-02-11
BR9714004A (pt) 2000-05-02
ATE420956T1 (de) 2009-01-15

Similar Documents

Publication Publication Date Title
NO20074906L (no) Polynukleotid som koder for et kimaert molekyl, vertcelle som uttrykker et kimaert molekyl og rekombinant vektor omfattende polynukleotidet
CY1106216T1 (el) 5´ ESTs ΓΙΑ ΜΗ ΙΣΤΟ-ΕΙΔΙΚΕΣ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ
IL190793A0 (en) A fusion polypeptide comprising a collagen binding domain and an angiogenesis modulating domain
DK0797676T3 (da) Rekombinant adenoviral vektor og fremgangsmåder til anvendelse deraf
DK0932678T3 (da) En familie af gener kodende for apoptoserelaterede peptider, peptider kodet deraf og fremgangsmåde til anvendelse deraf
ATE407949T1 (de) Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
DE69841982D1 (de) Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie
WO1999055868A3 (en) Fizz proteins
AU6871401A (en) Ev-vegf nucleic acids and polypeptides and methods of use
ATE411392T1 (de) Pockenviren mit zielgerichteter infektionsspezifität
CY1105398T1 (el) 5΄ ESTs ΓΙΑ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ ΠΟΥ ΕΚΦΡΑΖΟΝΤΑΙ ΣΕ ΔΙΑΦΟΡΟΥΣ ΙΣΤΟΥΣ
ATE307886T1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
PL296926A1 (en) Cloning and expression of dna molecules encoding enzymes of fungous origin causing degradation of arabinane
ATE517122T1 (de) Modifizierte cea-nukleinsäure und entsprechende expressionsvektoren
MXPA03000979A (es) Moleculas tipo receptor de complemento c3b/c4b y usos de las mismas.
WO2002094859A3 (en) Mage-a1 peptides for treating or preventing cancer
WO1996009391A3 (en) Dna sequence and protein of the non-structural reading frame i of the human parvovirus b19
NZ513731A (en) Regulatory constructs comprising intron 3 of prostate specific membrane antigen gene
WO2001030966A3 (en) An engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system
SI1673391T1 (sl) Modificirana cDNA za visoke ekspresijske nivoje faktorja VIII in njegovih derivatov
MXPA03000980A (es) Moleculas tipo receptor de complemento c3b/c4b y usos de las mismas.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees